Fig. 4: Vβ8-CAR-T cells were effective in vivo against T cell leukemia.
From: T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
a Schematic depiction of the Vβ8-CAR-T cell treatment schedule and sample analysis. b, c Female NSG mice aged 6–8 weeks (n = 6 mice/group) were intravenously inoculated with 2 × 106 Jurkat cells. Seven days later, tumor-bearing mice were treated with 1 × 107 untransduced T cells or Vβ8-CAR-T cells. Twenty days after treatment, bone marrow cells, spleen cells, and PBMCs were collected to analyze the Jurkat (hCD45+Vβ8+) tumor cell burden (c). The data shown represent the mean ± SEM (n = 6 mice/group). Statistical significance was determined by the two-sided Mann–Whitney U test. Representative results of one from two replicate experiments are shown. d, e Female NSG mice aged 6–8 weeks (n = 5 mice/group) were intravenously inoculated with 2 × 106 Jurkat-IRFP-Luc tumor cells. Seven days later, tumor-bearing mice were treated with 1 × 107 untransduced or Vβ8-CAR-T cells. Bioluminescence images were acquired and analyzed at the indicated time points (d, e). Statistical significance was determined by two-sided, two-way ANOVA with Sidaks multiple comparisons test. Representative results of one from two replicate experiments are shown. f Kaplan–Meier OS curves are shown for the inoculated mice (n = 6 mice for control T group and n = 10 mice for Vβ8-CAR-T group). Statistical significance was determined by the two-sided Mantel–Cox test. Pooled data from two replicate experiments are shown.
